Simvastatin preserves myocardial perfusion and coronary microvascular permeability in experimental hypercholesterolemia independent of lipid lowering.

[1]  J. Slattery,et al.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.

[2]  E L Ritman,et al.  Coronary microvascular functional reserve: quantification of long-term changes with electron-beam CT preliminary results in a porcine model. , 2001, Radiology.

[3]  C. Napoli,et al.  Hypercholesterolemia impairs myocardial perfusion and permeability: role of oxidative stress and endogenous scavenging activity. , 2001, Journal of the American College of Cardiology.

[4]  A. M. Lefer,et al.  Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease. , 2001, Cardiovascular research.

[5]  L. Lerman,et al.  Simvastatin Preserves Coronary Endothelial Function in Hypercholesterolemia in the Absence of Lipid Lowering , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[6]  E. Ritman,et al.  Minimally Invasive Evaluation of Coronary Microvascular Function by Electron Beam Computed Tomography , 2000, Circulation.

[7]  G. Dell'omo,et al.  Simvastatin, capillary permeability, and acetylcholine‐mediated vasomotion in atherosclerotic, hypercholesterolemic men , 2000, Clinical pharmacology and therapeutics.

[8]  J. Rumberger,et al.  Effects of acute and chronic angiotensin receptor blockade on myocardial vascular blood volume and perfusion in a pig model of coronary microembolization. , 2000, American journal of hypertension.

[9]  S. Higano,et al.  Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. , 2000, Circulation.

[10]  HOMAS,et al.  The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels , 2000 .

[11]  Ames,et al.  PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA , 2000 .

[12]  R. Laaksonen,et al.  Low-density lipoprotein-independent effects of statins. , 1999, Current opinion in lipidology.

[13]  L. Kuo,et al.  cAMP-independent dilation of coronary arterioles to adenosine : role of nitric oxide, G proteins, and K(ATP) channels. , 1999, Circulation research.

[14]  W. Aengevaeren.  Beyond lipids - the role of the endothelium in coronary artery disease. , 1999, Atherosclerosis.

[15]  M. Bell,et al.  Validation of minimally invasive measurement of myocardial perfusion using electron beam computed tomography and application in human volunteers , 1999, Heart.

[16]  E L Ritman,et al.  Measurement of in vivo myocardial microcirculatory function with electron beam CT. , 1999, Journal of computer assisted tomography.

[17]  A. Zeiher,et al.  Clinical importance of coronary endothelial vasodilator dysfunction and therapeutic options , 1999, Journal of internal medicine.

[18]  R. Schwartz,et al.  Coronary artery apoptosis in experimental hypercholesterolemia. , 1999, Atherosclerosis.

[19]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[20]  R. Schwartz,et al.  Experimental hypercholesterolemia induces ultrastructural changes in the internal elastic lamina of porcine coronary arteries. , 1998, Atherosclerosis.

[21]  A. Gotto,et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.

[22]  R. Gibbons,et al.  Coronary endothelial dysfunction in humans is associated with myocardial perfusion defects. , 1997, Circulation.

[23]  K. Dellsperger,et al.  Mechanism of coronary microvascular responses to metabolic stimulation. , 1997, Cardiovascular research.

[24]  J. Leppo.  Comparison of pharmacologic stress agents , 1996, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

[25]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[26]  H. Crijns,et al.  Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris. REGRESS Study Group. , 1996, Circulation.

[27]  H. Kempen,et al.  Effects of simvastatin on plasma lipids and apolipoproteins in familial hypercholesterolemic swine. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[28]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .

[29]  M. Creager,et al.  Endothelial release of nitric oxide contributes to the vasodilator effect of adenosine in humans. , 1995, Circulation.

[30]  A. Weyman,et al.  Incremental doses of dobutamine induce a biphasic response in dysfunctional left ventricular regions subtending coronary stenoses. , 1995, Circulation.

[31]  G J Boerma,et al.  Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). , 1995, Circulation.

[32]  Y. T. Lee,et al.  Early change of vascular permeability in hypercholesterolemic rabbits. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[33]  U. Schwabe,et al.  Characterization of the adenosine receptor in microvascular coronary endothelial cells. , 1994, European journal of pharmacology.

[34]  J. Stengård,et al.  Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease , 1994, The Lancet.

[35]  M. Sugimachi,et al.  Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. , 1994, Circulation.

[36]  James P. Martucci,et al.  Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease. A potential noninvasive marker of healing coronary endothelium. , 1994, Circulation.

[37]  A. Lerman,et al.  Intact and altered endothelium in regulation of vasomotion. , 1992, Circulation.

[38]  P. Poole‐Wilson,et al.  Pathogenesis of Congestive State in Chronic Obstructive Pulmonary Disease: Studies of Body Water and Sodium, Renal Function, Hemodynamics, and Plasma Hormones During Edema and After Recovery , 1992, Circulation.

[39]  R. Wilson,et al.  Effects of adenosine on human coronary arterial circulation. , 1990, Circulation.

[40]  K. Zitnay,et al.  Loss of Selective Endothelial Cell Vasoactive Functions Caused by Hypercholesterolemia in Pig Coronary Arteries , 1988, Circulation research.

[41]  R. Ruffolo,et al.  The pharmacology of dobutamine. , 1987, The American journal of the medical sciences.

[42]  M. Marcus,et al.  Use of ultrafast computed tomography to quantitate regional myocardial perfusion: a preliminary report. , 1987, Journal of the American College of Cardiology.

[43]  M. Marcus,et al.  Precision of measurements of right and left ventricular volume by cine computed tomography. , 1986, Circulation.

[44]  S. M. Collins,et al.  Determination of left ventricular mass in dogs with rapid-acquisition cardiac computed tomographic scanning. , 1985, Circulation.